Syntaxin makes top appointments
Syntaxin, a UK developer of biopharmaceuticals that control cell secretion, has appointed Melanie Lee as chief executive.
Lee was formerly president of new medicines and executive vp of r&d at UCB, having served as r&d director at Celltech before its merger with UCB. She brings a wealth of drug research and development experience to Syntaxin, through her early academic career at Cancer Research UK (as ICRF), a decade in research with GlaxoSmithKline and her later role at Celltech.
Nigel Clark has been appointed as chief business officer and Jon Court has joined as chief development officer.
Clark was formerly vp of business development with Vernalis, while Court was previously founder and ceo of Fulcrum Pharma, a contract drug development business engaged in global small molecule and biopharmaceutical development, following r&d roles at Roche and Wellcome.
"The development and commercialisation of our novel cell secretion inhibitors in endocrine, inflammatory and neurological disorders will be strengthened through these three new executive appointments and our existing research and medical team," said Andrew Sandham, Syntaxin chairman.
You may also like
Sustainability
Ipsen and Pharnext to collaborate on Pleotherapy technology
<p>Ipsen, a French pharmaceutical group and Pharnext, a biopharmaceutical company specialising in the development of innovative treatments, have signed an exclusive research, development and marketing agreement on drug candidates for treating Charcot Marie-Tooth disease, issued from Pleotherapy technology.</p>
